Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Fresenius (FMS) Acquires 70% Stake In Kunming Wuhua Hospital

Published 04/06/2017, 09:49 PM
Updated 07/09/2023, 06:31 AM

Leading provider of dialysis products and services, Fresenius Medical Care AG & Co. KGAA (NYSE:FMS) , announced the acquisition of 70% equity interest in Kunming Wuhua Health Hospital in China. This is Fresenius Medical Care's first joint venture hospital in China.

Stock Performance

In the last three months, the price performance of Fresenius Medical was encouraging. The stock added 5.01% versus the Zacks classified Medical Instruments sub-industry’s gain of 4.71%.

However, the estimates revision trend for the stock lacks luster. The current quarter saw one estimate moving south over the last month, with no movement in the opposite direction. As a result, the Zacks Consensus Estimate for the current quarter dropped to 44 cents per share from 45 cents over the same time period.



More About the China Venture

Wuhua Hospital is a private Grade II hospital located in Wuhua district in the center of Kunming city. It is the capital of Yunnan province in south-west China.

The facility provides treatments to more than 8,000 chronic-disease patients and 70 dialysis patients. The scope of services includes internal medicine, nephrology, surgery, gynecology, dermatology, traditional Chinese medicine, physiotherapy, stomatology and others.

Fresenius Medical Care is a leading healthcare company, focusing on providing care to people with renal and other chronic conditions. The company has an extensive network of dialysis facilities, outpatient cardiac and vascular labs, urgent care centers, and the country’s largest collection of hospitalist and post-acute providers.

One of the world’s largest fully vertically integrated renal company, it offers specialty pharmacy and laboratory services, and manufactures and distributes the most comprehensive line of dialysis equipment, disposable products, and renal pharmaceuticals.

Key Picks

Currently, Fresenius Medical carries a Zacks Rank #3 (Hold). Better-ranked stocks in the broader medical sector are Inogen Inc. (NASDAQ:INGN) , IDEXX Laboratories, Inc. (NASDAQ:IDXX) and Fluidigm Corporation (NASDAQ:FLDM) . Notably, Inogen and IDEXX Laboratories sport a Zacks Rank #1 (Strong Buy) while Fluidigm carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Inogen has a long-term expected earnings growth rate of 17.50%. Notably, the stock registered an impressive one-year return of 70.6%.

IDEXX Laboratories has a long-term expected earnings growth rate of 15.04%. Additionally, the stock returned an impressive 97.5% in the last one year.

Fluidigm has a long-term expected earnings growth rate of 25%. The stock delivered a positive earnings surprise of 1.6% last quarter.

Zacks’ Best Private Investment Ideas

While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.

Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Click here for Zacks' private trades >>



Fresenius Medical Care Corporation (FMS): Free Stock Analysis Report

IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report

Inogen, Inc (INGN): Free Stock Analysis Report

Fluidigm Corporation (FLDM): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.